Real life evidence of Tab Ribociclib for Safety and Efficacy in a tertiary care centre (RERISE study).

In this retrospective observational study, data will be collected from patients who have Hormone positive, HER2 negative metastatic breast cancer and who have received Ribociclib along with endocrine treatment from Jun 2018 till Dec 2022.

Patients with altleast one available medical record on EMR will be included in the analysis. Progression free survival and overall survival will be studied.

Response will be assessed post evaluation of age, menopausal status, baseline tumor characteristics, ECOG, metastatic sites, comorbidities, previous anticancer treatment like surgery, radiation, chemotherapy lines received, ET lines, other ongoing treatments for comorbidities, visceral, non visceral disease .

 Data will be collected through EMR from all available records and reports such as blood investigations, radiological reports, physician notes and histopathological reports to assess the primary objective of the trial. Progression free survival will be calculated from the day of starting of Ribociclib to date of first disease progression either clinical or radiological. Overall survival and best response will be assessed. Toxicity will be graded as per CTCAE V 4.03. Adverse events and tolerability will be assessed along with time to recover from the toxicity. Dose reductions and interruptions will be studied.